A-Fib Linked to Worse Outcomes for Patients With Heart Failure, MR Undergoing Valve Repair

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 24, 2025.

via HealthDay

THURSDAY, July 24, 2025 -- For patients with heart failure and severe mitral regurgitation (MR) undergoing transcatheter edge-to-edge repair (M-TEER), baseline atrial fibrillation (AF) is associated with more frequent MR recurrence and an increased risk for death or heart failure hospitalization (HFH), according to a study published online July 17 in the Journal of the American Heart Association.

Carlo Mannina, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues examined the impact of baseline AF in patients with severe MR undergoing M-TEER in a study involving 156 patients with symptomatic heart failure. The composite outcome of death or HFH was the primary end point.

MR etiology was primary and secondary in 44.2 and 55.8 percent of patients, respectively. Overall, 37.8 percent of patients had AF or atrial flutter at baseline. The researchers found that M-TEER was successful in 98.3 and 96.9 percent of 59 and 97 patients with and without AF, respectively. The primary end point occurred in 64 patients during a median follow-up of 12.5 months, including death and HFH in 16 and 57 patients (10.3 and 36.5 percent), respectively. Baseline AF was a significant independent predictor of death or HFH (adjusted hazard ratio, 2.03). Among patients in sinus rhythm but not those in AF, left ventricular end-diastolic volume, left atrial volume, and right ventricular systolic pressure decreased during follow-up. There was an association for AF with an increased risk for severe MR recurrence (18.6 versus 8.2 percent).

"These findings support early treatment of heart failure and mitral regurgitation before atrial fibrillation develops, in addition to considering ablation should atrial fibrillation occur," coauthor Gregg W. Stone, M.D., also from the Icahn School of Medicine, said in a statement.

Several authors disclosed ties to the pharmaceutical and medical device industries.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-07-25 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords